PDF Cover

Ioversol Market

The market for Ioversol was estimated at $461 million in 2024; it is anticipated to increase to $668 million by 2030, with projections indicating growth to around $911 million by 2035.

Report ID:DS1806049
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Ioversol
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Ioversol Market Outlook

Revenue, 2024

$461M

Forecast, 2034

$856M

CAGR, 2025 - 2034

6.4%

The Ioversol industry revenue is expected to be around $490.1 million in 2025 and expected to showcase growth with 6.4% CAGR between 2025 and 2034. The escalating evolution of the Ioversol market underscores its growing significance in the industry, propelled by its variety of potential applications. Several key driving factors are contributing to this steady inclination: breakthroughs in diagnostic imaging technologies, a resurgence in demand for minimally invasive procedures, and an aging global population that is predisposed to chronic diseases. These elements collectively enhance the ongoing relevance and potential impact of Ioversol on the global market scenario, thus illustrating the substantial market dynamics and consumer demand for this compound.

As a nonionic, low-osmolar contrast medium, Ioversol, also known as Optiray, is pivotal in numerous medical applications, predominantly in diagnostic radiology and imaging procedures. It consistently offers key features such as high quality imaging, lower toxicity, and enhanced patient tolerance. Moreover, major applications include but are not only limited to vascular angiography, urography, arthrography, and computerized tomography. Recent market trends show an inclination towards personalized and precision medicine, fostering the adoption of Ioversol in diagnostic imaging.

Ioversol market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Ioversol Market Outlook

Market Key Insights

  • The Ioversol market is projected to grow from $460.6 million in 2024 to $857 million in 2034. This represents a CAGR of 6.4%, reflecting rising demand across Neurology, Cardiology, and Urology.

  • Guerbet is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Ioversol market and are expected to observe the growth CAGR of 4.2% to 6.1% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 7.4% to 8.8%.

  • Industry players are pushing the adoption of transitions like The Shift towards Radiology for future years due to existing low growth of 6.4% ; but are also expected to invest $27 million by 2030.

  • The Ioversol market is set to add $396 million between 2024 and 2034, with manufacturer targeting Cardiology & Urology Application projected to gain a larger market share.

  • With

    rising demand for diagnostic imaging, and

    Advancements in Imaging Technology, Ioversol market to expand 86% between 2024 and 2034.

ioversol market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Ioversol - Country Share Analysis

Opportunities in the Ioversol

The global market for contrast media like Ioversol has also witnessed steady growth, particularly in developed regions. However, emerging markets in regions such as Africa, Latin America, and South Asia remain largely untapped. Increasing healthcare budgets and improving healthcare infrastructure in these regions present significant growth opportunities for Ioversol.

Growth Opportunities in North America and Europe

The North American region holds a significant share in the global Ioversol market, attributed to the sophisticated healthcare infrastructure, technological advancement, and high awareness levels concerning diagnostic procedures. Besides, the presence of key manufacturers stimulating competition, such as GE Healthcare and Bayer AG, contributes to the growth of Ioversol usage in the region. The constantly advancing medical imaging technologies and proliferation in the incidence of cardiovascular diseases further drive Ioversols demand. American Thoracic Societys new guidelines encouraging the use of Ioversol in diagnostic testing could be a potential game-changer, potentially presenting new opportunities for growth in this sector.
Europe represents another growth-centric region for the Ioversol market, in part due to its stringent regulatory environment and high emphasis on quality healthcare services. The European market displays a competitive landscape with leading players like Bracco Imaging and Guerbet actively participating. Furthermore, the rapidly expanding geriatric population and the subsequent rise in the demand for non-invasive diagnostic methods have amplified Ioversols importance. The recent shift towards personalized diagnostic protocols further propels the utilization of Ioversol, thus showcasing a positive growth outlook in the region.

Market Dynamics and Supply Chain

01

Driver: Growing Demand for Advanced Imaging Procedures and Rising Prevalence of Chronic Diseases

One of the primary drivers for the ioversol market is also the growing demand for advanced diagnostic imaging procedures alongside the rising prevalence of chronic diseases. Hospitals, diagnostic centers, and specialty clinics are also increasingly adopting CT scans, angiography, and urography to enable accurate and early diagnosis. Separately, the global rise in cardiovascular, neurological, and urological disorders has also fueled the need for contrast-enhanced imaging to identify structural abnormalities and guide treatment. Technological advancements in nonionic, low-osmolality contrast agents like ioversol further enhance patient safety and image quality, supporting adoption in sensitive populations such as elderly or renal-impaired patients. Together, the convergence of advanced imaging adoption and increased chronic disease incidence is also driving demand for ioversol, as clinicians require reliable, high-resolution imaging solutions to improve diagnostic accuracy and therapeutic outcomes.
Another key driver is also the rapid expansion of minimally invasive and image-guided interventional procedures across neurology, cardiology, and urology. Techniques such as catheter-based interventions, stent placements, and targeted biopsies rely heavily on precise imaging, which increases the demand for high-quality contrast agents like ioversol. Its nonionic, water-soluble formulation ensures enhanced visibility and reduces the risk of adverse reactions during these procedures. The trend toward outpatient and less invasive diagnostic approaches is also driving hospitals and specialty centers to stock reliable contrast media, creating sustained growth opportunities for ioversol in modern interventional care.
02

Restraint: Concerns Over Contrast‑Induced Nephropathy and Safety Limit Use in Vulnerable Patients

A key restraint for the ioversol market is ongoing concern over contrast‑induced nephropathy, especially in patients with pre‑existing renal impairment. Although ioversol is a low‑osmolality, nonionic agent, clinicians often limit its use or choose alternative imaging techniques to avoid potential kidney injury. For example, elderly patients with chronic kidney disease may be referred for MRI or ultrasound instead of contrast‑enhanced CT, reducing overall demand. These safety concerns influence hospital protocols, slow adoption in high‑risk populations, and can compress revenue growth for contrast media suppliers as facilities prioritize safer or non‑contrast modalities.
03

Opportunity: Strategic Collaborations for Research and Development and Technological Innovations in Medical Imaging

The market for Ioversol can further expand through strategic collaborations with research institutions and biotech firms. These partnerships can foster research and development, leading to innovative applications of Ioversol in medical diagnoses and therapies. Extending the utility of this contrast agent beyond its traditional applications can improve market penetration and stimulate growth.
Rapid advances in medical imaging technologies necessitate the continued use and development of effective contrast media. Ioversol, widely used in angiographic procedures, can tap into this by aligning with technological innovations. Developments in areas like nanotechnology could allow for enhanced contrast imaging and targeted delivery, providing tangible growth prospects for Ioversol.
04

Challenge: Intense Competition from Alternative Contrast Agents Reduces Market Share Growth

Another significant restraint is intense competition from other iodine‑based and non‑iodine contrast agents that offer similar or improved imaging performance. Brands such as iohexol, iopamidol, and newer macrocyclic gadolinium agents for MRI present clinicians with multiple choices, pressuring ioversol’s market share and pricing power. For instance, radiology departments may select contrast media based on negotiated pricing or supplier contracts rather than clinical preference, reducing ioversol penetration. This competitive landscape limits pricing flexibility, compresses profit margins, and alters purchasing behavior, slowing overall market expansion amid aggressive marketing and supply agreements by rival manufacturers.

Supply Chain Landscape

1

Raw Material Sourcing

Mallinckrodt Pharmaceuticals BASF
2

Drug Manufacturing

Guerbet
3

Packaging and Distribution

PCI Pharma ServicesSharp Packaging Services
4

End-User Applications

NeurologyCardiologyUrology
Ioversol - Supply Chain

Use Cases of Ioversol in Neurology & Cardiology

Neurology : Ioversol is widely used in neurological imaging procedures due to its high radiopacity and safety profile. In neurology, it is primarily employed as a nonionic, water-soluble contrast agent for CT and angiographic studies, helping visualize brain structures and cerebral vasculature. Hospitals, diagnostic centers, and specialized neurology clinics use ioversol to enhance imaging clarity, which aids in the diagnosis of conditions such as stroke, aneurysms, and tumors. Its low osmolality reduces the risk of adverse reactions in sensitive patients, making it a preferred choice for neurological imaging procedures where precision and patient safety are critical.
Cardiology : In cardiology, ioversol is mainly used in coronary angiography and cardiac CT scans to visualize blood vessels and assess heart function. Nonionic formulations of ioversol provide superior image quality and reduce potential nephrotoxicity, making it ideal for patients with pre-existing kidney concerns. Cardiology centers and hospitals rely on ioversol to detect blockages, assess coronary artery disease, and guide interventional procedures. Its rapid clearance and high contrast enhancement help cardiologists obtain detailed images for accurate diagnosis and treatment planning, improving patient outcomes in cardiovascular care.
Urology : Ioversol is applied in urology for imaging procedures such as intravenous urography, CT urography, and cystography. The nonionic contrast agent enables clear visualization of the urinary tract, including kidneys, ureters, and bladder, helping detect obstructions, stones, or tumors. Urology clinics, hospitals, and radiology departments use ioversol to enhance diagnostic accuracy while minimizing adverse reactions. Its favorable safety profile, combined with excellent contrast resolution, allows clinicians to perform detailed examinations efficiently. This supports precise treatment planning and monitoring of urological conditions, improving patient care and diagnostic confidence.

Recent Developments

Recent developments in the Optiray market show increased adoption in advanced diagnostic imaging, especially cardiovascular and neurovascular CT and angiography. A key trend is the shift toward low‑osmolality, nonionic contrast agents that improve image clarity while reducing adverse reactions in sensitive patients. Growing demand for minimally invasive procedures and enhanced clinical decision support tools is driving broader use of ioversol across hospitals, radiology centers, and specialty clinics, reinforcing its role in precision diagnostics and patient‑centric care.

October 2025 : Guerbet published its Revenue at September 30, 2025, reporting continued sales performance with strong momentum for products such as Optiray amid broader imaging portfolio growth, confirming financial targets and strategic direction for the year.
March 2025 : Guerbet released its 2024 full‑year results, showing solid revenue growth of €841.1 million and improved profitability driven by demand for its contrast agents, including Optiray.
October 2024 : Guerbet reported Revenue at September 30, 2024, confirming robust sales and continued demand for contrast media such as ioversol products in diagnostic imaging.

Impact of Industry Transitions on the Ioversol Market

As a core segment of the Other Healthcare industry, the Ioversol market develops in line with broader industry shifts. Over recent years, transitions such as The Shift towards Radiology and Enhancement in Cardiovascular Applications have redefined priorities across the Other Healthcare sector, influencing how the Ioversol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

The Shift towards Radiology

The radiological applications for Ioversol are skyrocketing, following technological advancements in imaging procedures. This contrast agent, primarily used in medical diagnosis and therapy, is increasingly being employed in CT scans, angiography, and Xrays. Furthermore, its demand within the radiology realm is driven by its optimal opacification, better patient tolerance, and fewer sideeffects.
02

Enhancement in Cardiovascular Applications

The increasing use of ioversol in cardiovascular applications marks a significant shift in diagnostic imaging practices. Traditional imaging methods often faced limitations in visualizing intricate coronary structures, but ioversol’s nonionic, water-soluble formulation provides high contrast clarity during angiography and cardiac CT scans. Hospitals, cardiology centers, and interventional labs have benefited from this transition, enabling precise detection of blockages, aneurysms, and structural anomalies. Additionally, medical device manufacturers and interventional equipment providers have seen increased demand as enhanced imaging supports catheter-based procedures and stent placements. This trend not only improves patient outcomes but also drives growth across related healthcare sectors, including radiology, surgical planning, and clinical training programs.